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Abstract: This retrospective, multicenter observational study aimed to describe the outcomes of
surgical and medical treatment of C. acnes-related prosthetic joint infection (PJI) and the potential
benefit of rifampin-based therapies. Patients with C. acnes-related PJI who were diagnosed and
treated between January 2003 and December 2016 were included. We analyzed 44 patients with
C. acnes-related PJI (median age, 67.5 years (IQR, 57.3–75.8)); 75% were men. The majority (61.4%)
had late chronic infection according to the Tsukayama classification. All patients received surgical
treatment, and most antibiotic regimens (43.2%) included β-lactam. Thirty-four patients (87.17%)
were cured; five showed relapse. The final outcome (cure vs. relapse) showed a nonsignificant
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trend toward higher failure frequency among patients with previous prosthesis (OR: 6.89; 95% CI:
0.80–58.90) or prior surgery and infection (OR: 10.67; 95% IC: 1.08–105.28) in the same joint. Patients
treated with clindamycin alone had a higher recurrence rate (40.0% vs. 8.8%). Rifampin treatment
did not decrease recurrence in patients treated with β-lactams. Prior prosthesis, surgery, or infection
in the same joint might be related to recurrence, and rifampin-based combinations do not seem to
improve prognosis. Debridement and implant retention appear a safe option for surgical treatment
of early PJI.
Keywords: Cutibacterium acnes; prosthetic joint infection; surgical and medical treatment
1. Introduction
Cutibacterium (formerly known as Propionibacterium) acnes is an anaerobic Gram-
positive bacillus and a skin commensal organism with a predilection for pilosebaceous
follicles, and it was formerly considered a contaminant. Moreover, C. acnes has been identi-
fied as a cause of biomaterial-related infections (BRIs) involving arthroplasty, cerebrospinal
fluid (CSF) shunts, and spinal instrumentation, among others [1–3]. In recent years, with
improved diagnosis methodology, including prolonged incubation protocols, C. acnes has
become the microorganism most frequently related to infections involving shoulder pros-
theses. This infection type has become an emerging problem, but the relevant data are still
limited [1,4,5].
Cutibacterium infections are usually characterized by a paucity of classical infections
or inflammation symptoms, and they are often characterized by the absence of elevated
inflammatory markers [1,6].
The role of C. acnes in prosthetic joint infections (PJIs) might be underestimated for
the following reasons: (1) it is a common contaminant of the skin; (2) it needs a special
transport medium; (3) it has delayed growth (up to 14 days); (4) the cultures need to be
rechecked or discarded within 3 to 5 days of incubation. The advent of matrix-assisted laser
desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the routine
diagnosis of bacterial infections in clinical laboratories has increased the speed and ease of
anaerobic bacteria identification [4,7,8].
Cutibacterium appears to have a greater predilection for infections involving the shoul-
der joint compared to other anatomical regions. The risk factors for C. acnes-related
orthopedic infection include a history of joint surgery prior to the index surgery and male
sex [9,10].
C. acnes is usually susceptible to a wide range of common antibiotics but there are
no clinical trials or extensive observational studies that allow us to know the best antibi-
otic regimen or surgical procedure in these patients. The Infectious Diseases Society of
America (IDSA) guidelines recommend penicillin or ceftriaxone as first-line treatment for
C. acnes-related PJIs, with clindamycin or vancomycin as alternatives, and minocycline
or doxycycline for suppressive therapy [11]. However, there have also been reports of
increased antimicrobial resistance in biofilm-associated C. acnes isolates in vitro. In vitro
and animal models of C. acnes biofilms suggest the efficacy of rifampin against C. acnes-
related foreign-body infections [12,13], but adjunctive rifampin therapy is not included in
the IDSA recommendations for C. acnes-related PJI management.
Despite its antimicrobial susceptibility, C. acnes is sometimes remarkably difficult to
eradicate; therefore, medical management of PJIs without surgical intervention has been
considered to result in poorer clinical outcomes [2].
The aim of this study was to describe the epidemiological, clinical, and biological
characteristics, as well as the outcomes of surgical and medical treatment, of C. acnes-related
PJI and the potential benefit of rifampin-based therapeutic combinations.
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2. Results
Forty-six cases of C. acnes-related PJI were identified, of which two patients were
excluded because both had co-infections with a microorganism other than CNS. Finally,
we included 44 patients with C. acnes-related PJI. The median patient age was 67.5 years
(IQR, 57.3–75.8); 75% of the patients were men. The number of cases included, according to
year, is shown in Figure 1.
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Figure 1. Cases frequency by year.
2.1. Patient Baseline and Clinical Characteristics
Demographic data, comorbidities, risk factors predisposing to PJI, signs and symp-
toms, and laboratory data at presentation are shown in Table 1. Most cases were classified
as late chronic infection (type 2) or positive intraoperative culture (type 4), with 25% being
acute prosthetic infections according to the Tsukayama classification. However, accord-
ing to the Zimmerli classification, the most frequent type of infection was early infection
(52.3%), while delayed and late infections were present in 47.7% of cases.
Table 1. Demographic, clinical, and laboratory characteristics of shoulder PJI due to C. acnes.
Variable No (%) a
Age, years b 67.5 (IQR, 57.3–75.8)
Male 33 (75)
Charlson Index b 3.0 (IQR, 0.0–4.0)
Comorbidities
Diabetes mellitus 13 (29.5)
Oncologic diseases 8 (18.2)
Renal insufficiency 3 (6.8)
Immunosuppressive treatment 2 (4.5)
Others 14 (31.8)
Time to diagnosis, days b 78.0 (IQR, 10.0–431.0)
Previous prosthesis 5 (11.4)
Previous surgery 5 (11.4)
Previous infections 5 (11.4)
Prosthesis infection
Right shoulder 24 (54.5)
Left shoulder 20 (45.5)
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Table 1. Cont.
Variable No (%) a
Clinical characteristics
Fever 8 (18.2)
Joint pain 33 (75)
Swelling 23 (52.3)
Fistula 7 (15.9)
Purulent wound drainage 12 (27.3)
Laboratory parameters b
WBC count, cells/mm3 8245.0 (IRQ, 6427.5–10,367.5)
CRP, mg/dL 14.0 (IQR, 6.0–32.3)
ESR, mm/h 46.0 (IQR, 22.0–71.0)
Type of shoulder PJI
• Tsukayama classification
Early postoperative infection 11 (25.0)
Late chronic infection 27 (61.4)
Positive intraoperative infection 6 (13.6)
• Zimmerli classification
Early infection 23 (52.3)
Delayed or low-grade infection 14 (31.8)
Late infection 7 (15.9)
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell. a Data are
the number (%) of cases. b Median (IQR, interquartile ranges).
2.2. Microbiological Characteristics and Antimicrobial Susceptibility Patterns
With regard to microbiological data, diagnosis was performed preoperatively and/or
intraoperatively in all patients. In 17 (38.6%) of the 44 patients, C. acnes was found in
the joint fluid aspiration. In 42 (95.5%) of 44 patients, C. acnes was found in intraop-
erative samples. There were 15 patients with C. acnes isolation in both samples (joint
and intraoperative).
Three or more positive cultures were obtained in 32 patients (72.7%), two cultures
were obtained in seven patients (15.9%), and only one culture was obtained in five patients
(11.4%), where the infection was demonstrated by histopathologic inflammation and posi-
tive sonicate fluid from the prosthetic material culture. All tested isolates were susceptible
to β-lactams (penicillin), vancomycin, and rifampin (Table 2).
Table 2. Samples and microbiological characteristics of shoulder PJI due to C. acnes.
Variable Patients No. (%) a
Samples taken for culture
Joint aspirate fluid 17 (38.6)
Intraoperative sample 42 (95.5)
Joint fluid + intraoperative samples 15 (34.1)
Microorganisms isolated
Only P. acnes 35 (79.5)







Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicro-
bial susceptibility testing. a Data are the number (%) of cases; susceptibilities determined as per CLSI/EUCAST
breakpoints. b All antibiotics were not tested in all strains isolated.
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2.3. Surgical and Medical Therapy
All patients received surgical treatment: two-stage procedure (38.6%), debridement
and implant retention (DAIR) (36.4%), one-stage procedure (18.2%), arthrodesis (2.3%),
and resection arthroplasty (4.5%). When we compared the surgical treatment received
with the type of infection according to the Tsukayama classification, there was an expected
association between performing DAIR and early postoperative infection (Table 3).
Table 3. Comparison between the types of treatment with type of infection of shoulder PJI due to C. acnes.
Treatment
Type of Infection No. (%) a
Total (n = 44) p
Type 4 b (n = 6) Type 2 b (n = 27) Type 1 b (n = 11)
Antibiotic
Amoxicillin 3 (50.0) 13 (48.1) 3 (27.3) 19 (43.2) 0.558
Clindamycin 3 (50.0) 8 (29.6) 3 (27.3) 14 (31.8) 0.650
Rifampin 2 (33.3) 11 (40.7) 6 (54.5) 19 (43.2) 0.677
Surgical
Debridement and retention 0 6 (22.2) 10 (90.9) 16 (36.4) 0.000
2-stage procedure 1 (16.7) 15 (55.6) 1 (9.1) 17 (38.6) 0.013
1-stage procedure 4 (66.7) 4 (14.8) 0 (0) 8 (18.2) 0.006
Arthrodesis 0 1 (3.7) 0 (0) 1 (2.3) 1
Resection arthroplasty 1 (16.7) 1 (3.7) 0 (0) 2 (4.5) 0.315
a Data are the number (%) of cases. b Tsukayama classification: early postoperative infection (Type 1), late chronic infection (Type 2), and
positive intraoperative cultures (Type 4).
The majority (43.2%) of antibiotic regimens used β-lactam (amoxicillin), while clin-
damycin was used in 31.8% and other antibiotics (linezolid, quinolones, doxycycline, and
glycopeptides—vancomycin and teicoplanin) were used in 22.7%. Rifampin was adminis-
tered concurrently with at least one of the aforementioned antibiotics in 19 patients (43%),
with two cases of rifampin treatment being discontinued due to adverse reactions. When
we compared the type of antibiotic treatment with the type of infection, we observed no
significant differences (Table 3). The median duration of antibiotic therapy was 56 days
(IQR, 44–84 days).
2.4. Treatment Outcomes
Among the 44 patients included, 39 were evaluable for treatment outcome. At the
last follow-up, five patients were lost, 34 patients were considered cured, and five had
microbiologically confirmed recurrence. Three patients died due to noninfectious causes
(acute pulmonary edema, advanced renal neoplasm, and cardiorespiratory arrest); these
patients were followed up for more than 12 months with favorable infection outcomes.
We compared patients with a favorable outcome to those who failed treatment
(Table 4). All patients in the failure group were male, but there was no significant differ-
ence in the clinical presentation, treatment received, or type of infection. A nonsignificant
trend toward a higher frequency of failure was observed among patients with previous
prosthesis (odds ratio (OR): 6.89; 95% confidence interval (CI): 0.80–58.90; p = 0.078) and
previous surgery and infection in the same joint (OR: 10.67; 95% IC: 1.08–105.28; p = 0.043).
In addition, we observed a higher frequency of recurrence in diabetic patients (OR: 4.87;
95% IC: 0.69–34.50; p = 0.113) and those who were treated only with clindamycin (OR:
6.89; 95% IC: 0.80–58.90; p = 0.078) than those who only received amoxicillin (OR: 0.357;
95% CI: 0.04–3.55; p = 0.379) or rifampin-based combinations (OR: 0.844; 95% CI: 0.12–5.72;
p = 0.862).
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Table 4. Comparison of final outcomes.
Outcome
Variable Cured(N = 34)
Recurrence
(N = 5) p
Age, years (Median) 68 (IQR, 57.8–76.3) 69 (IQ, 42.5–73.5) 0.378
Gender, No. (%)
Male 24 (70.6) 5 (100) 0.302
Female 10 (29.4) 0 (0)
Charlson Index (Median) 2.95 (IQR, 0–4.03) 2.0 (IQR, 0–4.50) 0.729
Comorbidities, No. (%)
Diabetes 8 (23.5) 3 (60) 0.125
Renal insufficiency 2 (5.9) 1 (20) 0.345
Oncologic disease 7 (20.6) 0.563
Immunosuppressive therapy 2 (5.9) 1
Previous prosthesis, No. (%) 3 (8.8) 2 (40) 0.114
Previous surgery, No. (%) 2 (5.9) 2 (40) 0.072
Previous infections, No. (%) 2 (5.9) 2 (40) 0.072
Prosthesis infection, No. (%)
Right shoulder 18 (53) 3 (60) 1
Left shoulder 16 (47) 2 (40)
Time to diagnosis, days (Median) 67 (IQR, 9–199) 70 (IQR, 7–1537) 0.823
Type of infection No. (%)
• Tsukayama classification 1
Early postoperative infection 10 (29.4) 1 (20.0)
Late chronic infection 20 (58.8) 3 (60.0)
Positive intraoperative cultures 4 (11.8) 1 (20.0)
• Zimmerli classification 0.823
Early infection 19 (55.9) 3 (60)
Delayed or low-grade infection 11 (32.4) 1 (20)
Late infection 4 (11.8) 1 (20)
Surgical treatment, No. (%)
Prosthesis retention 13 (38.2) 2 (40) 1
1-stage procedure 5 (14.7) 1 (20) 1
2-stage procedure 13 (38.2) 2 (40) 1
Arthrodesis 1 (2.9) 0 1
Resection arthroplasty 2 (5.9) 0 1
Antimicrobial treatment, No. (%)
Amoxicillin 14 (41.2) 1 (20) 0.631
Clindamycin 3 (8.8) 2 (40) 0.114
Other 2 (5.9) 0 1
Amoxicillin plus rifampin 3 (8.8) 1 (20) 0.436
Clindamycin plus rifampin 5 (14.7) 1 (20) 1
Other plus rifampin 7 (20.6) 0 0.563
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Regarding surgical treatment, 15/39 patients (38.5%) underwent DAIR, with 13 having
favorable outcomes (Figure 2). When analyzed according to both classifications, for patients
classified by the Tsukayama guidelines, 9/13 cured patients (69.23%) had type 1 infections
and 4/13 (30.77%) had type 2, with one case of recurrence for type 1 and another recurrence
for type 2. According to the Zimmerli classification, 12/13 of the cured patients (92.30%)
had early infections and 1/13 (7.7%) had a delayed infection, with both recurrences being
classified as early infections. Of the 24 patients treated with prosthesis removal, only three
had recurrence (12.5%) (Table 4).
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Figure 2. Flowchart of failure rates a cording to the e i ical approaches used. * Fifteen patients were treat d
with a two-stage procedure, six were treated with a o - re, one was treated with arthrodesis, and two were
treated with resection arthroplasty.
Among the 39 evaluable patients, 17 were treated with rifampin. There were no differ-
ences in the outcome of patients treated with rifampin-based combinations. There were
five patients with positive intraoperative cultures, with one being treated with rifampin
therapy and cured, while the others (4/5) did not receive rifampin and recurrences were
observed. Of the 15 patients treated with DAIR, eight (53.3%) received rifampin-based
regimens, while seven did not, and one recurrence was observed in each group, but this
was not significant (Figure 2). We analyzed 11 patients who received clindamycin treatment
(six associated with rifampin) and there were three instances of recurrence (all isolates were
susc ptible to clindamycin).
The epidemiological, clinical, and tr atment data of the five patients who sho ed
recurrence are pres nted in Table 5.
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Table 5. Individual clinical characteristics and treatment of the five recurrence cases.
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14 Type 1 Earlyinfection DAIR Clindamycin 175
Abbreviations: DM, diabetes mellitus; CKD, Chronic kidney disease. a Mean age (SD), 60.2 (SD 17.6) years. b Tsukayama classification:
early postoperative infection (Type 1), late chronic infection (Type 2), and positive intraoperative cultures (Type 4).
3. Discussion
In this retrospective multicenter study, we described 44 patients with shoulder PJI due
to C. acnes over a period of 14 years. The diagnosis of this infection is difficult due to the
absence of classical clinical evidence, as well as the challenges associated with culturing
the microorganism. In this 14 year series, we observed an increase in the number of
diagnosed cases of this infection, which is probably due to the extended incubation time
that has been demonstrated in other studies for maximizing the recovery of C. acnes from
PJI specimens [1,7,14–17].
Previous studies have argued that the shoulder has a propensity for infection with C.
acnes because it is the anaerobic dominant bacteria from healthy skin, particularly in moist
areas (axilla), where a higher C. acnes bacterial burden is observed in men compared to
women [17–19]. Moreover, previous series have reported that male gender is a risk factor
for the development of this infection [1,9,20]. These previous findings would explain our
results in which a male predominance of PJI was observed.
The most frequent types of infection in this study, according to the Tsukayama clas-
sification, were late chronic or positive intraoperative cultures, which is similar to that
reported in other studies [1,21,22]; this is due to the paucity of classical symptoms and
the absence of elevated inflammatory markers that delay diagnosis. However, when we
classified the infection type according to the Zimmerli classification, early infection was
the most frequent.
In our study, the most frequent symptom was joint pain. This is consistent with other
studies in which pain and functional limitations without either fever or constitutional
symptoms were the most frequent clinical presentations [6,7,23].
Previous surgery in the same joint has been linked to an increased risk of C. acnes-
related PJI because repeated manipulation of the joint causes changes in the anatomical
structure; this increases the duration of surgery, which is a major risk factor for shoulder
PJI from this microorganism [20,24,25]. We observed that previous prosthesis, infection, or
surgery in the same joint might be related with recurrence, but we could not demonstrate a
significant association, possibly due to small sample size.
In our study, all isolates tested were susceptible to penicillin, vancomycin, and ri-
fampin, with approximately 2.5% being resistant to clindamycin. These observed suscep-
tibility patterns were similar to those of other studies [1,7,22], which suggested that the
broad antimicrobial susceptibility of C. acnes appeared to be maintained.
Previous clinical studies and case reports provide little information regarding the
optimal treatment for C. acnes-related PJI. In our study, all patients received antibiotic and
surgical treatment. As expected, we observed significant differences between surgery type
(DAIR, two-stage surgery, and one-stage surgery), as well as the type of prosthetic infection.
Regarding surgical treatment, prosthesis retention and the two-stage procedure were the
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most frequent surgical procedures performed, unlike previous articles, which suggests that
prosthesis exchange should be the treatment of choice in most cases [2,5,26]. We observed
that, in the cases of early infection according to the Zimmerli classification, DAIR treatment
may be a safe option.
In terms of antimicrobial treatment, the outcomes with or without adjunctive rifampin
therapy were similar to other studies [1,22]. This finding is striking, particularly in cases
treated with debridement and implant retention, because this antibiotic has antibiofilm
activity and its effectiveness for the eradication of C. acnes has been demonstrated both
in vitro and in vivo in an animal model of foreign-body infection [12]. However, another
explanation could be that the presence of a high inoculum in the biofilms forms in a foreign
body (i.e., a prosthetic joint). In this state, the microorganism produces mutations that
can lead to some degree of resistance, which is observed as a reduced susceptibility to
rifampin; this phenomenon was reported in a study by Furustrand et al. [27], where it was
demonstrated in vitro.
On the other hand, we observed a nonsignificant trend toward a higher frequency of
failure among 11 patients who received clindamycin (cured 72.7% vs. recurrence 27.3%).
The IDSA guidelines recommend clindamycin as an alternative treatment to β-lactams, be-
cause the majority of tested isolates were susceptible; for this reason, the use of clindamycin
has been evaluated in previous studies [1–3]. However, future clinical trials will be needed
to compare antibiotic therapy between β-lactams and clindamycin in C. acnes-related PJI.
The strength of this multicenter study is that only patients with a proven diagnosis of C.
acnes-related PJI were included. Currently, most studies include all types of bone infection
due to this microorganism, which makes it difficult to determine the best management and
evolution of this entity.
This study did have some limitations. This was a retrospective observational study
that did not have predefined therapeutic procedures, and this could have induced bias.
Moreover, the follow-up time was limited to a 1 year period. However, in PJIs caused by
microorganisms as paucisymptomatic as C. acnes, in which DAIR has been performed, a
longer follow-up time might be necessary.
4. Methods
4.1. Study Design, Patients, and Settings
This multicenter, retrospective observational study was conducted at 16 hospitals
belonging to the Prosthetic Joint Infection Group of the Spanish Network for Research in
Infectious Diseases between January 2003 and December 2016.
Patients aged 18 years and older with shoulder PJIs that were caused by C. acnes
and diagnosed between January 2003 and December 2016 were included, regardless of
the age of the implant at the time of the initial symptoms. Polymicrobial infections with
coagulase-negative staphylococci (CNS) were also included.
4.2. Data Collection
Cases were identified by searching the databases of previously recorded consecutive
PJIs or the general archives at each participating hospital.
Medical chart abstraction was performed using a standardized case report form to re-
trieve demographic, clinical, and laboratory data. Demographic data included age and sex.
Laboratory data included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
and white blood cell (WBC) counts. Clinical data consisted of comorbidities, immunosup-
pressive therapy, Charlson index, previous exposure to antibiotics (7 days), hospitalization
in the previous 90 days (of at least 2 days), and receipt of hemodialysis. We also collected
the following information regarding arthroplasty: date of implantation, site, primary or
revision arthroplasty, previous infections in the same joint (date and microorganism),
cemented versus uncemented arthroplasty, use of antibiotics in bone cement, and date
of diagnosis. The time from index surgery to diagnosis was recorded as the time from
the last surgical procedure performed pre diagnosis to the first positive C. acnes culture,
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with classification of the PJI, type and number of cultured samples, and their results also
being recorded.
Information regarding surgical treatment, exchange of removable pieces of the pros-
thesis (in at least one debridement surgery), and the type and duration of antimicrobials
used was also collected, as well as patient outcomes and the date of the last follow-up visit.
4.3. Definitions
A PJI was defined on the basis of previously detailed criteria [1,11]. The C. acnes
etiology was confirmed if ≥2 specimens were positive for C. acnes, or if one culture
specimen was positive for C. acnes, with no other organism detected on culture and
concurrent evidence of joint purulence, histopathological inflammation, or a sinus tract
communicating with the prosthesis. PJI was assigned according to the Tsukayama and
Zimmerli classifications [28–30].
4.4. Follow-Up and Treatment Success
Antimicrobial therapeutic regimens and treatment outcomes were assessed through
the last recorded clinical visit. Decisions on therapeutic regimens were based on the clinical
judgment of the infectious disease and surgical specialist providers. The type, delivery
method, and duration of antimicrobial therapy were recorded.
After being discharged, patients were followed-up according to the protocol of each
participating center. The follow-up period was calculated from surgery due to infection:
debridement, one-stage exchange, two-stage exchange, or other procedures (arthrode-
sis/resection arthroplasty). Among patients in remission, only those with at least 1 year of
follow-up were included in the outcome analysis.
Cure was defined as the absence of signs and symptoms of infection at the conclusion
of a minimum 1 year follow-up period after antibiotic therapy, which did not result in
unplanned additional surgical debridement for putative persistent infection. Treatment
failure was established on the basis of the following criteria: (1) persistence of symptoms
and clinical signs of infection during treatment that led to a change in the surgical strategy
(except for new surgical debridement during the first month after an initial debridement);
(2) the recurrence of symptoms and clinical signs of infection once the surgical strategy
was completed, with isolation of the same microorganism; (3) the need for suppressive
antibiotic treatment against C. acnes; (4) infection-related death. Any case of reinfection
by microorganisms other than C. acnes detected during the follow-up period was not
considered a failure.
4.5. Microbiological Methods
Culture specimens were collected and processed at each participating institution,
following the Spanish guidelines for the microbiological diagnosis of bone and joint infec-
tions [31,32]. Identification testing of isolates was performed in the clinical microbiology
laboratory at each center using standard microbiological techniques. The susceptibilities of
C. acnes isolates were tested against standard antimicrobial agents. Isolates were classified
as susceptible according to the minimum inhibitory concentration (MIC) breakpoints set
by the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on
Antimicrobial Susceptibility Testing (EUCAST).
4.6. Statistical Analysis
The descriptive analysis for defining the patient’s characteristics was done by fre-
quencies and percentages for categorical variables and measures of central tendency and
dispersion for numerical variables. The non-normally distributed continuous variables
were expressed by median and interquartile range (IQR). For evaluating the differences
between favorable outcome and failed treatment, the Mann–Whitney U test was used to
compare continuous variables and the chi-squared and Fisher exact tests were used for
comparing categorical variables. Moreover, univariate logistic regression was used for
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evaluating the recurrence risk. A p-value <0.05 was considered statistically significant.
Statistical analyses were performed using SPSS software version 26 (IBM Inc., Armonk,
NY, USA).
5. Conclusions
Physicians should be aware of the increase in the frequency of shoulder PJIs caused by
C. acnes because there are few clinical symptoms and an absence of elevated inflammatory
markers. On the other hand, patients with type 1 infections according to the Tsukayama
classification or early infection by the Zimmerli classification could be treated with DAIR.
According to our data, rifampin therapy does not seem to improve outcomes, and clin-
damycin seems to be associated with a worse prognosis. Randomized studies with a greater
number of patients are necessary to establish the optimal antimicrobial treatment.
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